AgomAb Therapeutics NV

AgomAb Therapeutics NV (AGMB) priced its initial public offering on Feb 6, 2026 at $16.00 per ADS, within its $15.00–$17.00 range, raising $200M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $779.8M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley and Leerink Partners. Davis Polk and Clifford Chance advised the underwriters.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.

Status

IPO

Ticker

AGMB

Exchange

Nasdaq Global Select

Priced

Feb 6, 2026

IPO price

$16.00 per ADS

Price range

$15.00–$17.00

Raised

$200M

Market cap at IPO price

$779.8M

First filed

Jan 16, 2026

Underwriters

J.P. Morgan, Morgan Stanley and Leerink Partners

Underwriters' counsel

Davis Polk and Clifford Chance

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.